WT1 and acute myeloid leukemia: We confirmed the same prognostic relevance of WT1-MRD negativity before Allo-SCT in a subsequent study performed in FLT3-mutated AML, in which the median OS and DFS in the WT1-MRD-negative group were not reached and were 10.2 and 5.5 months, respectively, in the WT1-MRD-positive group (p = 0.0005 and p = 0.0001, respectively) [37].